Tarsus Pharmaceuticals (TARS) Accounts Payables (2023 - 2026)

Tarsus Pharmaceuticals' Accounts Payables history runs 4 years deep, the most recent figure standing at $24.1 million for Q1 2026.

• In Q1 2026, Accounts Payables changed N/A year-over-year to $24.1 million; the TTM figure through Mar 2026 stood at $24.1 million (changed N/A YoY), while the FY2025 annual figure was $16.4 million, up 73.98% from the prior year.
• Accounts Payables for Q1 2026 stood at $24.1 million, up from $16.4 million in the prior quarter.
• The five-year high for Accounts Payables was $24.1 million in Q1 2026, with the low at $400000.0 in Q1 2023.
• The 4-year median for Accounts Payables is $12.9 million (2024), against an average of $12.6 million.
• Peak annual rise in Accounts Payables reached 73.98% in 2025, while the deepest fall reached 73.98% in 2025.
• Tarsus Pharmaceuticals' Accounts Payables stood at $400000.0 in 2023, then jumped by 2254.75% to $9.4 million in 2024, then soared by 73.98% to $16.4 million in 2025, then surged by 47.26% to $24.1 million in 2026.
• Business Quant data shows TARS's Accounts Payables at $24.1 million in Q1 2026, $16.4 million in Q4 2025, and $9.4 million in Q4 2024.